Avastin offers hope to CME sufferers

Article

Intravitreal bevacizumab (Avastin; Genentech) appears to be a safe and effective treatment in the management of refractory inflammatory cystoid macular oedema.

Intravitreal bevacizumab (Avastin; Genentech) appears to be a safe and effective treatment in the management of refractory inflammatory cystoid macular oedema (CME), according to a report published in the January issue of Retina.

Friederike Mackensen from the University of Heidelberg and colleagues from the University of Duisburg-Essen, Duisburg, Germany reviewed 11 eyes of 10 patients with persistent CME who subsequently had been treated with intravitreous bevacizumab 1.25 or 2.5 mg. Improvement was gauged by visual acuity (VA) gain ≥2 lines and central retinal thickness reduction, as observed by optical coherence tomography (OCT).

Reductions in central retinal thickness were observed as early as two weeks, with a mean foveal thickness reduction of 127.2 µm at four-weeks. Concurrent improvement in VA was observed in four of the 10 subjects and was unchanged in others. Four patients received two injections and five patients received three injections. Except for progression of cataract in one eye, no ocular or systemic adverse events were recorded.

The researchers believe that intravitreal bevacizumab could offer a safe and effective treatment for the management of refractory inflammatory CME, despite the effect being transient.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.